nivolumab,rp1
bms
['ignyte']
 therapy was found to be safe and tolerable. this initial data formed the basis for further exploration that is currently ongoing in the ignyte-eso study, investigator sandra p. d angelo, md, tells cgtl.
watch the interview now #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.